Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 5/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787885 | 0.90 | MCHR1 (0.37) | MCHR1SMN1; SMN2NPSR1MAPTLMNA | |
| SCHEMBL4740848 | 0.90 | MCHR1 (0.36) | MCHR1SMN1; SMN2NPSR1MAPTLMNA | |
| SCHEMBL4236062 | 0.89 | MCHR1 (0.47) | MCHR1SMN1; SMN2NPSR1MAPTMCHR2 | |
| SCHEMBL4233894 | 0.89 | MCHR1 (0.47) | MCHR1SMN1; SMN2NPSR1MAPTMCHR2 | |
| SCHEMBL4236975 | 0.88 | MCHR1 (0.47) | MCHR1SMN1; SMN2NPSR1MCHR2FGFR1 | |
| SCHEMBL4233256 | 0.88 | MCHR1 (0.49) | MCHR1SMN1; SMN2NPSR1MAPTMCHR2 | |
| SCHEMBL4228574 | 0.88 | MCHR1 (0.46) | MCHR1SMN1; SMN2NPSR1MCHR2FGFR1 | |
| SCHEMBL4235333 | 0.88 | SMN1; SMN2 (0.52) | MCHR1SMN1; SMN2NPSR1FGFR1TP53 | |
| SCHEMBL4233245 | 0.87 | MCHR1 (0.46) | MCHR1SMN1; SMN2NPSR1MCHR2FGFR1 | |
| SCHEMBL4238167 | 0.87 | MCHR1 (0.52) | MCHR1SMN1; SMN2NPSR1MAPTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | MCHR1 47/4885SMN1; SMN2 1538/4885NPSR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.